+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Mesenchymal Stem Cells (MSC) - Global Strategic Business Report

  • PDF Icon

    Report

  • 202 Pages
  • February 2025
  • Region: Global
  • Global Industry Analysts, Inc
  • ID: 2769226
The global market for Mesenchymal Stem Cells (MSC) was valued at US$5.3 Billion in 2024 and is projected to reach US$10.6 Billion by 2030, growing at a CAGR of 12.2% from 2024 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions.

Global Mesenchymal Stem Cells (MSC) Market - Key Trends and Drivers Summarized

Mesenchymal stem cells (MSCs), a type of adult stem cell found in various tissues such as bone marrow, adipose tissue, and umbilical cord tissue, hold significant promise for regenerative medicine and therapeutic applications across a spectrum of medical conditions. These cells are prized for their ability to self-renew and differentiate into a variety of cell lineages, including bone, cartilage, muscle, and nerve cells. Their potential is particularly compelling because they can evade immune rejection, a critical factor that enhances their suitability for clinical applications. The ability of MSCs to differentiate is influenced by various factors, including the source of the cells and the conditions under which they are cultured. This process is governed by complex genetic and epigenetic mechanisms that regulate their activation, proliferation, and maturation.

MSCs also exhibit immunomodulatory properties that are crucial for suppressing immune responses and fostering tissue repair, making them valuable in the treatment of autoimmune diseases, spinal cord injuries, and cardiovascular diseases. They promote angiogenesis and tissue regeneration, underscoring their importance in managing diverse medical conditions. MSCs are sourced from a range of tissues, each offering unique advantages and challenges in terms of isolation and expansion. However, their clinical application is hindered by challenges such as cellular heterogeneity, variability, and the need for quality control. To harness the therapeutic potential of MSCs effectively, it is essential to develop standardized methodologies and conduct rigorous safety evaluations.

In the oncological arena, MSCs present a dual role. They have been shown to contribute to tumor growth by promoting angiogenesis, immune evasion, and creating a tumor-supportive microenvironment. Conversely, they exhibit anti-tumor properties, deploying cytokines and other cytotoxic elements to target cancer cells. This dual nature necessitates a nuanced understanding of MSC behavior to optimize their therapeutic use in cancer treatment. Researchers are exploring innovative strategies to leverage MSCs as delivery vehicles for anti-cancer agents, transforming them into 'Trojan horses' that can carry therapeutic payloads directly to tumors. The combination of MSCs with biomaterials, which can scaffold the cells and control the release of therapeutic agents, presents a promising avenue to overcome current therapeutic limitations and enhance the efficacy of cancer treatments.

Report Scope

The report analyzes the Mesenchymal Stem Cells (MSC) market, presented in terms of market value (USD). The analysis covers the key segments and geographic regions outlined below.

Segments

Source of MSC Isolation (Bone Marrow, Adipose Tissues, Fetal Liver, Lung, Cord Blood, Other Sources of MSC Isolation); Application (Disease Modelling, Drug Development & Discovery, Stem Cell Banking, Tissue Engineering, Toxicology Studies, Other Applications).

Geographic Regions/Countries

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Key Insights:

  • Market Growth: Understand the significant growth trajectory of the Bone Marrow Source segment, which is expected to reach US$3.4 Billion by 2030 with a CAGR of a 13.2%. The Adipose Tissues Source segment is also set to grow at 14.7% CAGR over the analysis period.
  • Regional Analysis: Gain insights into the U.S. market, valued at $1.5 Billion in 2024, and China, forecasted to grow at an impressive 11.4% CAGR to reach $1.6 Billion by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.

Why You Should Buy This Report:

  • Detailed Market Analysis: Access a thorough analysis of the Global Mesenchymal Stem Cells (MSC) Market, covering all major geographic regions and market segments.
  • Competitive Insights: Get an overview of the competitive landscape, including the market presence of major players across different geographies.
  • Future Trends and Drivers: Understand the key trends and drivers shaping the future of the Global Mesenchymal Stem Cells (MSC) Market.
  • Actionable Insights: Benefit from actionable insights that can help you identify new revenue opportunities and make strategic business decisions.

Key Questions Answered:

  • How is the Global Mesenchymal Stem Cells (MSC) Market expected to evolve by 2030?
  • What are the main drivers and restraints affecting the market?
  • Which market segments will grow the most over the forecast period?
  • How will market shares for different regions and segments change by 2030?
  • Who are the leading players in the market, and what are their prospects?

Report Features:

  • Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2024 to 2030.
  • In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
  • Company Profiles: Coverage of players such as Cell Applications Inc., Celprogen Inc., Cyagen US Inc., Genlantis Inc., Lonza Group and more.
  • Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.

Some of the 56 companies featured in this Mesenchymal Stem Cells (MSC) market report include:

  • Cell Applications Inc.
  • Celprogen Inc.
  • Cyagen US Inc.
  • Genlantis Inc.
  • Lonza Group
  • Mesoblast Limited
  • MilliporeSigma
  • Neuromics
  • Orthofix International N.V.
  • PromoCell GmbH
  • R&D Systems Inc.
  • ScienCell Research Laboratories
  • Stemcell Technologies Inc.
  • Stemedica Cell Technologies Inc.
  • Thermo Fischer Scientific Inc.

Table of Contents

I. METHODOLOGYII. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • Global Economic Update
  • Mesenchymal Stem Cells (MSC) - Global Key Competitors Percentage Market Share in 2025 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
  • Regenerative Medicine Advances Propel Demand for Mesenchymal Stem Cells
  • Aging Global Population Drives Growth in MSC-Based Therapies
  • Technological Breakthroughs in Stem Cell Proliferation and Preservation Enhance MSC Therapeutic Viability
  • Expanding Clinical Trials Spotlight Efficacy of MSCs in Diverse Diseases
  • Rising Prevalence of Autoimmune Diseases Accelerates MSC Research and Applications
  • Growing Investment in Biotechnology Strengthens the Business Case for MSC Development
  • Collaboration between Academia and Industry Spurs Innovations in MSC Research
  • Enhanced Delivery Techniques Improve MSC Therapeutic Outcomes
  • Personalized Medicine Trends Catalyze Targeted MSC Therapy Developments
4. GLOBAL MARKET PERSPECTIVE
  • Table 1: World Mesenchymal Stem Cells (MSC) Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
  • Table 2: World Recent Past, Current & Future Analysis for Mesenchymal Stem Cells (MSC) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • Table 3: World Historic Review for Mesenchymal Stem Cells (MSC) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • Table 4: World 15-Year Perspective for Mesenchymal Stem Cells (MSC) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2015, 2025 & 2030
  • Table 5: World Recent Past, Current & Future Analysis for Bone Marrow by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • Table 6: World Historic Review for Bone Marrow by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • Table 7: World 15-Year Perspective for Bone Marrow by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
  • Table 8: World Recent Past, Current & Future Analysis for Adipose Tissues by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • Table 9: World Historic Review for Adipose Tissues by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • Table 10: World 15-Year Perspective for Adipose Tissues by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
  • Table 11: World Recent Past, Current & Future Analysis for Fetal Liver by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • Table 12: World Historic Review for Fetal Liver by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • Table 13: World 15-Year Perspective for Fetal Liver by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
  • Table 14: World Recent Past, Current & Future Analysis for Lung by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • Table 15: World Historic Review for Lung by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • Table 16: World 15-Year Perspective for Lung by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
  • Table 17: World Recent Past, Current & Future Analysis for Cord Blood by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • Table 18: World Historic Review for Cord Blood by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • Table 19: World 15-Year Perspective for Cord Blood by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
  • Table 20: World Recent Past, Current & Future Analysis for Other Sources of MSC Isolation by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • Table 21: World Historic Review for Other Sources of MSC Isolation by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • Table 22: World 15-Year Perspective for Other Sources of MSC Isolation by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
  • Table 23: World Recent Past, Current & Future Analysis for Disease Modelling by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • Table 24: World Historic Review for Disease Modelling by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • Table 25: World 15-Year Perspective for Disease Modelling by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
  • Table 26: World Recent Past, Current & Future Analysis for Drug Development & Discovery by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • Table 27: World Historic Review for Drug Development & Discovery by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • Table 28: World 15-Year Perspective for Drug Development & Discovery by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
  • Table 29: World Recent Past, Current & Future Analysis for Stem Cell Banking by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • Table 30: World Historic Review for Stem Cell Banking by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • Table 31: World 15-Year Perspective for Stem Cell Banking by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
  • Table 32: World Recent Past, Current & Future Analysis for Tissue Engineering by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • Table 33: World Historic Review for Tissue Engineering by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • Table 34: World 15-Year Perspective for Tissue Engineering by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
  • Table 35: World Recent Past, Current & Future Analysis for Toxicology Studies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • Table 36: World Historic Review for Toxicology Studies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • Table 37: World 15-Year Perspective for Toxicology Studies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
  • Table 38: World Recent Past, Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • Table 39: World Historic Review for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • Table 40: World 15-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
III. MARKET ANALYSIS
UNITED STATES
  • Mesenchymal Stem Cells (MSC) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
CANADA
JAPAN
  • Mesenchymal Stem Cells (MSC) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
CHINA
  • Mesenchymal Stem Cells (MSC) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
EUROPE
  • Mesenchymal Stem Cells (MSC) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
FRANCE
  • Mesenchymal Stem Cells (MSC) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
GERMANY
  • Mesenchymal Stem Cells (MSC) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
ITALY
UNITED KINGDOM
  • Mesenchymal Stem Cells (MSC) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
REST OF EUROPE
ASIA-PACIFIC
  • Mesenchymal Stem Cells (MSC) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
REST OF WORLDIV. COMPETITION

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Cell Applications Inc.
  • Celprogen Inc.
  • Cyagen US Inc.
  • Genlantis Inc.
  • Lonza Group
  • Mesoblast Limited
  • MilliporeSigma
  • Neuromics
  • Orthofix International N.V.
  • PromoCell GmbH
  • R&D Systems Inc.
  • ScienCell Research Laboratories
  • Stemcell Technologies Inc.
  • Stemedica Cell Technologies Inc.
  • Thermo Fischer Scientific Inc.

Table Information